Value through Innovation09 October 2015

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive


Investing in the development of innovative active ingredients: Boehringer Ingelheim opens a new technology centre in Biberach


Vargatef® (nintedanib*) approved in the EU for lung cancer patients with advanced adenocarcinoma after first-line chemotherapy

- For media outside UK, US and Canada only

Nintedanib* receives positive CHMP opinion in European Union for the treatment of IPF

- For media outside UK, US and Canada

Two new, large scale real-world analyses show fewer major bleeds and strokes with Pradaxa® than with warfarin

- For Non-US/Non-UK/Non-Canadian Media

New data show dabigatran-specific antidote idarucizumab* restores blood clotting mechanism in humans

- For Non-US/Non-UK/Non-Canadian Media

Boehringer Ingelheim "Runs" to support vital programs in Diabetes and Stroke


New subgroup analysis shows Asian non-small cell lung cancer patients with most common EGFR mutation (del19) lived significantly longer with first-line GIOTRIF® (afatinib*) compared to chemotherapy

- For Media In Asian Countries Only For Whom The Data Is Relevant For media outside the US, the UK & Canada only

Asthma: Boehringer Ingelheim announces U.S. FDA filing acceptance of NDA for Spiriva® Respimat® in asthma

- For media outside the US, the UK & Canada only

FDA Medicare study in 134,000 atrial fibrillation patients confirms positive safety profile and effectiveness of Pradaxa® in general practice

- Non-US/Non-UK/Non-Canadian Media

Boehringer Ingelheim and Lilly Revising Operational Structure of Diabetes Alliance in Certain Countries


Boehringer Ingelheim initiates global Phase III study investigating nintedanib* in patients with colorectal cancer refractory to standard treatments

- For Ex-US and Ex-UK Media Only

Winners of the 2014 European PRRS Research Award announced


Boehringer Ingelheim’s OFEV™ (nintedanib*) approved by the FDA for the treatment of idiopathic pulmonary fibrosis


- For media outside UK, US and Canada

Boehringer Ingelheim invests €100 million: Expanded Respimat® production in Dortmund


Head-to-head Phase III trial demonstrates superior progression-free survival for afatinib compared to erlotinib in patients with advanced squamous cell carcinoma of the lung

- For Ex-US and Ex-UK Media Only

Boehringer Ingelheim’s afatinib achieves primary endpoint in global Phase III study in recurrent/metastatic head and neck squamous cell cancer

- For Ex-US and Ex-UK Media Only

Nintedanib* receives positive CHMP opinion for second-line treatment of patients with adenocarcinoma of the lung

- For media outside UK and US only

Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy

- For Ex-US and Ex-UK Media Only